Strict blood pressure control is pivotal in the management of patients with aortic dissection (AD), but is frequently difficult to achieve. We determined antihypertensive medical therapy and levels of blood pressure (BP) control in 40 patients with chronic AD. Patient charts were reviewed for clinical variables, serial BP measurements, and antihypertensive drug therapy. Patients were divided into two groups: patients in group 1 had effective BP control (o135/80 mmHg), patients in group 2 had resistant hypertension (BPX135/80 mmHg despite prescription of at least three antihypertensive drugs). Overall, systolic BP (SBP) was 130720 mmHg, and diastolic BP (DBP) was 72713 mmHg. Patients received a median of 4 (1-6) antihypertensive drugs. b-blockers were used in 38/40 (95%) patients. Effective BP control was achieved in 24/40 (60%) patients (group 1), while 16/40 (40%) patients had resistant hypertension (group 2) despite receiving significantly more antihypertensive drugs (5 [4-6] vs 4 [1-5], P ¼ 0.001). Mean SBP was 11679 (101-132) mmHg in group 1 and 151713 (137-181) mmHg in group 2 (Po0.001); there was no difference in DBP. Group 2 patients had a significantly higher body mass index and were younger than patients in group 1. In conclusion, in the majority of patients with chronic AD, effective BP control can be achieved, but usually requires the combination of multiple antihypertensive drugs. However, in a significant proportion of patients (40%), who appear to be younger and more obese, medical therapy fails to achieve effective BP control despite use of a multiple drug regimen.
Introduction
Uncontrolled systemic hypertension has been identified as a main predictor of adverse long-term outcome in patients with aortic dissection (AD). 1, 2 Tight blood pressure (BP) control is thus of pivotal importance. 3 Recently, a target BP of o135/80 mmHg has been recommended for patients with chronic AD. 4 Effective BP control in patients with AD may, however, be challenging. Severe hypertension frequently occurs in acute AD, even in patients without history of hypertension. 5 So far, there are only limited data on the severity of systemic hypertension in patients with chronic AD. It has been suggested, that the severe hypertension observed with acute AD improves when the patient enters the chronic phase of the disease. 5 Although antihypertensive therapy constitutes the standard therapy for patients with chronic, uncomplicated AD, 3, 4 it is yet unknown in which proportion of patients effective BP control can be achieved. The appropriate drug regimen and extent of antihypertensive treatment required to achieve adequate BP control has not been described, so far. Clinical experience suggests that a combination drug therapy is usually required. 4, 6 It was the aim of the present study to assess the antihypertensive drug treatment regimen and level of BP control achieved in a large cohort of patients with chronic AD.
Methods

Patients
A total of 40 patients receiving treatment for chronic AD at the University Clinic Essen between January 1995 and November 2003 were included into the study. Diagnosis of AD was confirmed using standard criteria by at least two of the following examinations: 4 transoesophageal echocardiography (TEE), aortography, computed tomography (CT), or magnetic resonance imaging (MRI). Dissection was classified according to the Stanford classification. 7 AD was considered to be chronic at least 14 days after an initial episode of intense pain or -in the absence of such an event -after the diagnosis was first made. 4 All patients had to be on oral medication. Patients with intravenously administered drugs were excluded from this analysis.
Data evaluation
Patients charts were reviewed for the following clinical variables: gender, age, body mass index (BMI), cardiovascular risk factors, serum creatinine level, presence of coronary artery disease by angiography, systolic BP (SBP) and diastolic BP (DBP), and heart rate (HR). Adequately dosed drugs with BP lowering effect were recorded and classified into the following groups, according to World Health Organization (WHO):
8 b-blockers, calcium channel blockers (CCB), angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor antagonists (ARB), diuretics, a-blockers, and centrally acting agents (CAA, eg, imidazoline receptor stimulants, clonidine). Number and dosage of antihypertensives was recorded. BP and HR had been measured in a sitting position, after 5 min of rest, using an automated oscillometric monitor (Dinamap Compact, Critikon Ltd., Johnson and Johnson, USA). All measurements were performed using cuffs of appropriate sizes. The average of at least three BP recordings, taken on consecutive days during inhospital visits, was used for statistical analysis.
Blood pressure control
Patients were divided into two groups according to the level of BP control. BP control was defined as effective (group 1) when BP was o135/80 mmHg (according to recommendations of the European Society of Cardiology for the management of patients with chronic AD 4 ). Patients of group 2 were considered to have resistant hypertension, defined by insufficient lowering of SBP and DBP below the target BP of 135/80 mmHg despite implementation of lifestyle measures and prescription of at least three antihypertensive drug classes in adequate doses.
Statistical analysis
All continuous variables are presented as mean71 standard deviation (range) while categorical variables are described using frequencies and percentages. Comparisons between the two groups were made with the w 2 -or Fisher's exact test for categorical variables and two-tailed unpaired Student's t-test for continuous variables. All statistical analyses were performed using the SPSS software package (version 10.0, SPSS, Chicago, IL, USA). A P-value o0.05 was considered statistically significant.
Results
Study population
The clinical features of the patients in groups 1 and 2 are summarized in Table 1 . There were 32 male and eight female patients with an average age of 58.7711.9 (28-76) years. Two (5%) patients had chronic type A-AD, whereas 38 (95%) patients had chronic type B-AD. On average, AD occurred 37.5730.8 months (2.6-120.7) before inclusion into the study. Persistent perfusion of the false lumen was present in 39 (98%) patients.
Blood pressure
Mean SBP of all patients was 130720 (101-181) mmHg and the mean DBP was 72713 (48-105) mmHg. Two (5%) patients received a single-drug antihypertensive treatment; there were no patients treated without any BP lowering medication. A median of 4 (1-6) antihypertensive drugs were administered; 19 (48%) patients received X5 differ- 
Levels of BP control
A total of 24 (60%) patients had effective BP control (group 1) while 16 (40%) patients had ineffective BP control (group 2). Patients in group 2 had a significantly greater BMI and were younger than patients in group 1 ( Table 1 ). There were no other differences concerning demographic data or risk factors between the two groups ( Table 1) . Figure 1 , Table 2 ). In group 2, 12/16 (75%) of patients received X5 different drugs while in group 1 only 7/24 (29%) of patients received X5 different drugs (P ¼ 0.01, Figure 1 ). There was no difference in DBP or HR between the groups ( Table 2 ). The use of ACE inhibitors and a-blockers was significantly more frequent in patients of group 2 than in group 1 (Figure 2) .
Discussion
The present study shows that severe systemic hypertension is a significant therapeutical challenge in the long-term management of patients with AD. In the majority of patients, effective BP control can be achieved, but requires an antihypertensive drug combination therapy. In a substantial proportion (40%) of patients, however, resistant hypertension is present, and even a combination therapy of multiple antihypertensives fails to effectively control BP (Table 3) .
Severe, resistant hypertension has been previously observed in up to 64% of patients with acute AD, 5 even without history of prior hypertension. Januzzi et al, 5 however, suggested that the severe hypertension observed with acute AD improves when the patient enters the chronic phase of the disease. Contrary to the findings of Januzzi et al, the present study demonstrates that resistant hypertension is frequently observed in patients with chronic AD (40%), despite extensive antihypertensive medication. This is also supported by the findings of Grajek et al 6 who observed severe hypertension in 75% of their patients with chronic AD, with a mean BP of 195/117 mmHg under antihypertensive treatment. The higher proportion of severe hypertension compared to the present study may be explained by differences in the antihypertensive drug regimen between the two studies. Patients in the series by Grajek et al 6 received on average 3.170.9 antihypertensive drugs and only 10% of patients received X5 drugs. In the present study, patients received a median of four antihypertensives and 48% of patients received X5 different drugs. This may in summary suggest that effective BP control can be achieved in the majority of patients with chronic AD, but it requires the use of a multiple drug regimen.
We identified higher BMI and younger age as clinical risk factors of resistant hypertension. Obesity has been previously identified as a risk factor for decreased BP control. 9 It may be further speculated that younger patients who develop AD may have a more severe, underlying form of hypertension that may be more difficult to control per se. However, the actual mechanisms of severe hypertension in patients with chronic AD are unclear, so far. In the present study, patients with resistant hypertension Resistant hypertension in chronic aortic dissection H Eggebrecht et al had predominantly isolated systolic hypertension while DBP was effectively controlled. The isolated systolic hypertension may suggest higher pulse pressure and stiffer aortas in these patients. Retrospective data suggested an association with renal artery stenosis 10 which could, however, not be confirmed by others. 5 Recently, Wagner et al 11 reported elevated levels of plasma endothelin in patients with acute AD. However, the role of endothelin in resistant hypertension in patients with chronic AD has to be further elucidated. So far, there are only very limited data on the extent of antihypertensive drug therapy required to achieve adequate BP control in patients with AD. Bernard et al 1 reported that (only) 83% of their AD patients received any antihypertensive medication at all. In the present study, all (100%) patients were on antihypertensive drug treatment. However, a single-drug regimen was used in only two patients whereas the remaining 38 patients received a combination drug therapy, with almost half of the patients receiving X5 different drugs.
Regarding the choice of the appropriate drug regimen, b-blockers may offer many potential benefits in the treatment of patients with AD. b-blockers combine both negative inotropic (dP/dt) and BP lowering properties and have been shown to retard aortic expansion associated with Marfan's syndrome and that associated with chronic abdominal aortic aneurysms. 12 Observational studies also suggested reduced aortic enlargement and mortality in the long-term course of AD. 1, 13 The effect of b-blockers on limiting aneurysm progression may also be independent of changes in haemodynamics.
14 Previous experimental data suggested a direct effect of propranolol treatment on tissue matrix metabolism. 15 In the present study, b-blockers were used in 490% of patients. However, our data show that the administration of a b-blocker alone is not sufficient to achieve adequate BP control in patients with chronic AD.
2
Limitations
Although the present experience is one of the largest series reported so far, studies on patients with chronic AD are generally limited by a relatively small sample size due to the low incidence of the disease. The study is further limited by its retrospective and observational character. The study reports the incidence of prediagnosis hypertension, but does not describe its prediagnosis severity. Therefore, resistant hypertension may have also been present before the dissection occurred and may not be related to the dissection itself. We did not report on the long-term effects of severe hypertension with respect to disease progression or mortality; however, previous studies clearly identified uncontrolled hypertension as a main predictor of adverse long-term outcome. 2 Patient compliance is a critical issue when evaluating BP levels under antihypertensive therapy, particularly in patients receiving a combination of multiple drugs. Our study does not provide data on patient compliance and we cannot rule out that incompliance may have influenced on our results. However, all patients were seen on a regular basis and repetitively educated on the severity of the disease and the importance of tight BP control. We did not report 24-h BP measurements.
Clinical implications
Our study shows that systemic hypertension is a significant therapeutical challenge in patients with chronic AD and usually requires a combination drug therapy to achieve adequate BP control. A significant number of patients, who appear to be younger ACE -ACE inhibitors; CCB -calcium channel blockers; CAAcentrally acting agents; a -a blockers; ARB -angiotensin receptor blockers. Table 3 What is known on this subject: K Aortic dissection is a life-threatening disease with sobering long-term prognosis K Uncontrolled hypertension is a main risk factor of adverse outcome K Resistant hypertension is frequently observed during the acute phase of the disease What this study contributes to the literature: K In the majority of patients with chronic aortic dissection, effective blood pressure control is possible, but requires an antihypertensive drug combination therapy K A substantial proportion of dissection patients (40%) has severe hypertension, which is even resistant to a multiple drug regimen K Resistant hypertension is clinically associated with younger age and obesity
Resistant hypertension in chronic aortic dissection H Eggebrecht et al and more obese, have severe hypertension, which is even resistant to a combination of multiple antihypertensive drugs. Since tight BP control is of pivotal importance for patient's prognosis, a closer clinical follow-up with imaging of the aorta may be recommended in patients with resistant hypertension to detect any signs of progression of the dissection or impending complications as early as possible. Further, prospective studies are needed to elucidate whether patients with chronic AD and resistant hypertension would benefit from a more aggressive therapeutic approach (eg, endovascular stent-graft repair).
